News of Note—Bristol-Myers’ cancer vaccine, Bharat Biotech and more

non
In this week's news of note, a Bristol-Myers Squibb's cancer vaccine candidate enters human study. (Pixabay)

Here's some other vaccine news of note for the week.

> A Bristol-Myers Squibb cancer vaccine that has cured 97% of tumors in mouse studies has been approved for human trials at Stanford University. U.S. News & World Report article

> The WHO has recommended the introduction of the world’s first typhoid conjugate vaccine, Typbar-TCV, developed by Bharat Biotech, for infants and children over 6 months of age in typhoid-endemic countries. Release

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

> Sellas touted phase 2b results that showed its cancer vaccine NeuVax’s ability in prolonging disease-free survival when combined with Herceptin in a group of breast cancer patients. Endpoints News article

> The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the U.S. and Japan $3.2 million to develop a new malaria vaccine. Release

> Through a HK$98.75 ($12.6 million) fund, Hong Kong will provide free HPV vaccination to girls from low-income families. South China Morning Post article

> Archivel Farma has signed a deal with Laboratorios Silanes to develop and commercialize Ruti, a therapeutic vaccine against tuberculosis, in Mexico. Release

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

Iowa State University is working on a room-temp-stable nasal spray vaccine for COVID-19, and it recently tapped device maker Zeteo for support.

Pfizer's shot will go before an FDA expert panel on Dec. 10, with Moderna's review pegged for the 17th, Warp Speed chief Moncef Slaoui, Ph.D., said.